Weight loss drug makers Eli Lilly and Novo Nordisk on Thursday secured deals with the Trump administration to reduce prices for their blockbuster weight-loss drugs.

The deal was signed in exchange for tariff relief and wider access for Medicare patients.

Mike Doustdar, chief executive officer of Novo Nordisk, said in a statement that “Novo Nordisk has always worked to secure affordable access to our innovative medicines, and today’s announcement will bring semaglutide medicines to more American patients at a lower cost.

Lilly Chief Executive Officer Dave Ricks in a statement called the announcement a pivotal moment in US health care policy that was “made possible through collaboration with the Trump Administration.”

See Full Page